Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Avery S. Feit"'
Autor:
Kirsten Kubler, Agostina Nardone, Shankara Anand, Daniel Gorvich, Marjolein Droog, Francisco Hermida-Prado, Tara Akshi, Avery S Feit, Gabriella Cohen, Gwen Dackus, Matthew Pun, Yanan Kuang, Justin Cha, Mendy Miller, William J Gibson, Cloud P Paweletz, Eliezer M Van Allen, Flora E van Leeuwen, Petra Nederlof, Harry Hollema, Quang-Dé Nguyen, Marian JE Mourits, Ignaty Leshchiner, Chip Stewart, Ursula A Matulonis, Wilbert Zwart, Yosef E Maruvka, Gad Getz, Rinath Jeselsohn
Publikováno v:
Cancer Research. 82:GS2-09
Tamoxifen is widely used in the adjuvant treatment of estrogen receptor–positive (ER+) breast cancer and is an important drug for pre-menopausal women and post-menopausal patients who cannot tolerate aromatase inhibitors. Despite the clear clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c533d1be37ca1b1d6a88816bc753271
https://doi.org/10.1158/1538-7445.sabcs21-gs2-09
https://doi.org/10.1158/1538-7445.sabcs21-gs2-09
Autor:
Paloma Cejas, Avery S. Feit, Ariel Feiglin, X. Shirley Liu, Myles Brown, Yingtian Xie, Henry W. Long, Ningxuan Zhou, Nikolas Kesten, Len Taing, Yihao Li, Xintao Qiu, Joseph Perkins, Rinath Jeselsohn, Shengqing Gu
Publikováno v:
Genomics, Proteomics & Bioinformatics. 19:652-661
Chromatin immunoprecipitation sequencing (ChIP-seq) and the Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) have become essential technologies to effectively measure protein-DNA interactions and chromatin accessi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746db6738c13997a203e492e8474c348
https://doi.org/10.1016/j.gpb.2020.11.007
https://doi.org/10.1016/j.gpb.2020.11.007
Autor:
Sudeepa Syamala, Nadia Boufaied, Eva Corey, R. Jeffrey Karnes, Massimo Loda, Avery S. Feit, Tarek Hallal, Shengqing Gu, X. Shirley Liu, Connor Bell, Henry W. Long, Sheila Weinmann, Yingtian Xie, Qin Tang, Giorgia Zadra, Xintao Qiu, Paloma Cejas, Myles Brown, Kai W. Wucherpfennig, Adrienne M. Luoma, David P. Labbé, Anna de Polo, Mark Pomerantz, Elai Davicioni, Ji-Heui Seo, Daniel E. Spratt, Janie Larocque, Edward M. Schaeffer, Leigh Ellis, Matthew L. Freedman, Yi Zhang, Yang Liu, Edward P. O’Connor
c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression. Although MYC is overexpressed in both early and metastatic disease and associated with poor survival, its impact on prostate transcriptional reprogramming remains elusive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ebd7209d2c877a55f27c3bae905e193
https://doi.org/10.1101/2021.04.23.441016
https://doi.org/10.1101/2021.04.23.441016
Autor:
Myles Brown, Nikolas Kesten, Ariel Feiglin, Avery S. Feit, Paloma Cejas, Yingtian Xie, Ningxuan Zhou, Henry W. Long, X. Shirley Liu, Len Taing, Rinath Jeselsohn, Shengqing Gu, Xintao Qiu, Joseph Perkins, Yihao Li
ChIP-seq and ATAC-seq have become essential technologies used as effective methods of measuring protein-DNA interactions and chromatin accessibility. However, there is a need for a scalable and reproducible pipeline that incorporates correct normaliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ef39997fcb5ca03c758b5f7d42f8644
https://doi.org/10.1101/2020.11.06.367409
https://doi.org/10.1101/2020.11.06.367409
Autor:
Avery S. Feit, Teng Fei, X. Shirley Liu, Yiji Liao, Tengfei Xiao, Roodolph S. Pierre, Wei Li, Changmeng Cai, Pengya Xue, Melissa Duarte, Neel Shah, Jin Zhao, Philip W. Kantoff, Steven P. Balk, James Elliot Bradner, Han Xu, Henry W. Long, Chen-Hao Chen, Shaokun Shu, Shenglin Mei, Shuai Gao, Kexin Xu, Ji Hoon Lee, Zhijie Liu, Myles Brown, Kornelia Polyak, Mei Yang
SummaryDrugs that block the activity of the methyltransferase EZH2 are in clinical development for the treatment of non-Hodgkin lymphomas harboring gain-of-function EZH2 mutations that enhance its polycomb repressive function. In contrast, in castrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df40426e2c20bcfa188a435653183a96
https://doi.org/10.1101/2020.09.11.291534
https://doi.org/10.1101/2020.09.11.291534
Autor:
Alice Loo, Piotr Stepien, Avery S. Feit, David M. Sabatini, Johann Bergholz, Walter Michael, Monther Abu-Remaileh, Christopher Thomas Brain, Rinath Jeselsohn, Baishan Jiang, Deborah Butter, Michael D. Cameron, Carmine DeAngelis, Wojciech Michowski, Rachel Schiff, Deborah A. Dillon, Karolina Maria Nowak, Iga Stukan, Bojana Jovanovic, Jean J. Zhao, Tobias Otto, Nathanael S. Gray, Maria Ericsson, Anne Fassl, Piotr Sicinski, Ralph Tiedt, Myles Brown, Kornelia Polyak, Qing Sheng
Publikováno v:
Science Advances
This study presents strategies to render triple-negative breast cancers sensitive to CDK4/6 inhibitors.
Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor–positive breast cancers. In contr
Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor–positive breast cancers. In contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc4815f131efc64eea3d77fec1fe579f
http://hdl.handle.net/11588/857297
http://hdl.handle.net/11588/857297
Autor:
Ma Wen, Nanlin Li, C. Guarducci, Avery S. Feit, Rinath Jeseslsohn, Gabriella Cohen, Francisco Hermida-Prado, Hongliang Wei, Myles Brown, Wenting Pan, Agostina Nardone
Publikováno v:
Journal of Clinical Oncology. 38:1065-1065
1065 Background: The acquisition of ligand-independent ESR1 mutations during endocrine therapy in metastatic ER+ breast cancer is a common mechanism of resistance to endocrine treatment, particularly aromatase inhibitors, and found in more than 30% o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::815a31bb038416860d6bf7963387a5fd
https://doi.org/10.1200/jco.2020.38.15_suppl.1065
https://doi.org/10.1200/jco.2020.38.15_suppl.1065